Previous studies have implicated mutations or altered expression in individual enzymes, or alterations in specific signalling pathways (e.g., PI3K, AKT or mTOR) in driving the metabolic adaptations observed in a variety of cancers [16, 17, 77–79]. Here, MTOR is linked to cancer.